CSIMarket Company Name, Ticker, Competitors, else..
 
Alvotech  (NASDAQ: ALVO)
 

Alvotech's Suppliers Performance

ALVO's Supply Chain



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

 
ALVO Costs vs Sales of Suppliers Growth

• More on ALVO Suppliers






Alvotech's Comment on Supply Chain


The company utilizes single-use processing technology and obtains single-use components from various third-party suppliers. Some components have only one approved source, which may lead to shortages and delays. To address these risks and manage costs, the company is assessing redundancies. Reagents and materials for biologic medicines are sourced from third parties specializing in these commodities; although widely available, these materials may experience unforeseen shortages. AVT02 (adalimumab) and other pipeline products require auto-injector devices supplied under a proprietary design agreement with a current supplier. Master and working cell banks, essential for biologic manufacturing and regulatory approval, are produced at contract manufacturing organizations based in the EU or U.S. These cell banks are then transferred to the Reykjavik site in Iceland and the Jülich site in Germany to ensure supply continuity and redundancy. The availability of these cell banks is critical for commercial manufacturing.

Alvotech's Comment on Supply Chain


The company utilizes single-use processing technology and obtains single-use components from various third-party suppliers. Some components have only one approved source, which may lead to shortages and delays. To address these risks and manage costs, the company is assessing redundancies. Reagents and materials for biologic medicines are sourced from third parties specializing in these commodities; although widely available, these materials may experience unforeseen shortages. AVT02 (adalimumab) and other pipeline products require auto-injector devices supplied under a proprietary design agreement with a current supplier. Master and working cell banks, essential for biologic manufacturing and regulatory approval, are produced at contract manufacturing organizations based in the EU or U.S. These cell banks are then transferred to the Reykjavik site in Iceland and the Jülich site in Germany to ensure supply continuity and redundancy. The availability of these cell banks is critical for commercial manufacturing.







ALVO's vs. Suppliers, Data

(Revenue and Income for Trailing 12 Months, in Millions of $, except Employees)



COMPANY NAME MARKET CAP REVENUES INCOME EMPLOYEES
Alvotech 1,675.22 588.90 27.92 1,460
SUBTOTAL 0.00 0.00 0.00 -


Sources: Alvotech's official press releases and regulatory filings; CSIMarket.com's supply-chain research; and the financial filings and press releases of other companies cited in this report.
Updated on:
For your research, we’ve provided nine additional tables on Alvotech’s suppliers.
You can find them in the navigation menu under Suppliers.
To download the tables, please subscribe.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.